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Abstract
Background: Inflammatory responses are detected in the retina of patients with age-related macular degeneration
and Ccl2-/-/Cx3cr1-/- mice on rd8 background,(Ccl2-/-/Cx3cr1-/- mice) a model that develops progressive age-related
macular degeneration-like retinal lesions including focal photoreceptor degeneration, abnormal retinal pigment
epithelium and A2E accumulation. Tumor necrosis factor-inducible gene 6 protein is an anti-inflammatory protein
and has been shown to improve myocardial infarction outcome and chemically injured cornea in mice by
suppressing inflammation. In this study, we evaluated the effect of an intravitreous injection of recombinant TSG-6
on the retinal lesions of Ccl2-/-/Cx3cr1-/- mice.
Methods: Recombinant TSG-6 (400 ng) was administered by intravitreous injection into the right eye of six-week-
old Ccl2-/-/Cx3cr1-/- mice. Their left eye was injected with phosphate-buffered saline as a control. Funduscopic
pictures were taken before injection and sequentially once a month after injection. The mice were killed two
months after injection and the ocular histology examined. Retinal A2E, a major component of lipofuscin, was
measured by high performance liquid chromatography. The microarray of ocular mRNA of 92 immunological
genes was performed. The genes showing differentiated expression in microarray were further compared between
the injected right eye and the contralateral (control) eye by [real-time quantitative reverse transcription polymerase
chain reaction] qRT-PCR.
Results: The continuous monitoring of the fundus for two months showed a slower progression or alleviation of
retinal lesions in the treated right eyes as compared with the untreated left eyes. Among 23 pairs of eyes, the
lesion levels improved in 78.3%, stayed the same in 8.7% and progressed in 13.0%. Histology confirmed the clinical
observation. Even though there was no difference in the level of A2E between the treated and the untreated eyes,
microarray analysis of 92 immune genes showed that IL-17a was substantially decreased after the treatment.
Expression of TNF-a showed a similar pattern to IL-17a. The results were consistent in duplicated arrays and
confirmed by qRT-PCR.
Conclusions: We concluded that intravitreous administration of recombinant TSG-6 might stabilize retinal lesions
in Ccl2-/-/Cx3cr1-/- mice on rd8 background. Modulation of ocular immunological gene expressions, especially IL-17a,
could be one of the mechanisms.
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Background
Age-related macular degeneration (AMD) is a common
cause of irreversible central blindness in elderly patients
worldwide [1]. The pathological features of this neuro-
degenerative disease include degeneration and atrophy
of the photoreceptors and the retinal pigment epithe-
lium (RPE) in the macula. The advanced stage of AMD
presents as the exudative/neovascular or ‘wet’ form with
choroidal neovascularization, and the geographic atro-
phy or ‘dry’ form with loss of the photoreceptors and
RPE. Except for the suppression of choroidal neovascu-
larization, there are few options for AMD intervention.
Care for intermediate AMD and dry AMD is limited to
risk factor management. Smoking cessation, body mass
reduction, and specific vitamins and nutrient supple-
ments have been reported to slow disease progression
[2].
We have previously reported that genetically engi-
neered Ccl2-/-/Cx3cr1-/- mice on rd8 background
(Ccl2-/-/Cx3cr1-/-) developed a broad spectrum of AMD-
like pathology with early onset and high penetrance
[3-5]. The retinal abnormalities of this strain include
focal deep retinal lesions, photoreceptor disorganization
and degeneration, retinal pigment epithelial degenera-
tion and atrophy, A2E accumulation, and some with
choroidal neovascularization. The spontaneous retinal
lesions are generally symmetric in both eyes and become
worse with age. We have successfully demonstrated the
beneficial effects of long-term dietary intake of long-
chain omega-3 polyunsaturated fatty acids (n-3) to alle-
viate the retinal lesions of Ccl2-/-/Cx3cr1-/- mice. Chow
rich in n-3 was able to decelerate the retina lesions
observed by funduscopy, reserve the retinal structure
observed by histology and reduce the A2E level (retina
autofluorescence component) measured by HPLC [6].
We also reported that the subretinal injection of an
adeno-associated virus vector in which a portion of the
soluble vascular endothelial growth factor (VEGF) recep-
tor gene was cloned to trap excess VEGF-A either stabi-
lizes or arrests the progression of retinal lesions in
Ccl2-/-/Cx3cr1-/- mice [7]. This strain was on rd8 back-
ground (unpublished data), but exhibited 100% pene-
trance and more prominent focal lesions at an earlier
age compared with the rd8 with a single base deletion
in the Crb1 gene [8]. Due to the multiple functions of a
gene and disturbance of the whole pathway when key
genes are disrupted, the loss of Ccl2 and Cx3cr1 on rd8
background could cause the malfunction of pathways
other than the chemokine and chemokine receptor. This
is probably why a broad spectrum of pathological fea-
tures was observed in the inbred strain. We have char-
acterized the abnormalities in macrophage immunology,
oxidative stress and chaperone chemistry in the retinal
tissue of Ccl2-/-/Cx3cr1-/- mice [3,4,6,7,9-17]. The evi-
dence collected from previous studies on this mouse
model has encouraged us to test other potential options
for AMD therapy.
Inflammation, among other factors, has been sug-
gested to play an important role in AMD pathogenesis.
Elevated inflammatory mediators have been found in
the retinal tissues of AMD patients and Ccl2-/-/Cx3cr1-/-
mice [6,7,9,11,13]. Tumor necrosis factor-inducible gene
6 protein (TSG-6) was found to be anti-inflammatory
and has been shown to improve myocardial infarction
outcome and chemically injured cornea in mice by redu-
cing inflammation in the heart and cornea, respectively
[18-23]. In this study, we explored the potential benefi-
cial effect of intravitreal administration of TSG-6 on the
retinal lesion of Ccl2-/-/Cx3cr1-/- mice. Funduscopy, his-
tology, the level of retinal lipofuscin and determination
of immune response-related molecules were used to
evaluate the effects of the intervention.
Methods
Animals and treatment
Ccl2-/-/Cx3cr1-/- mice on rd8 background and wild type
control (C57BL/6) were bred in-house. The study was
conducted in compliance with the ARVO statement for
the use of animals, and all animal experiments were per-
formed under protocols approved by the Institutional
Animal Care and Use Committee of National Eye Insti-
tute, National Institutes of Health, USA.
A one-time intravitreous injection of 400 ng of recom-
binant TSG-6 (R&D Systems, (Minneapolis, MN, USA),
Cat. No. 2326-TS) in 1 μL volume was performed into
the right eye of six-week-old Ccl2-/-/Cx3cr1-/- mice on
rd8 background (n = 31). Their left eye was adminis-
tered 1 μL phosphate-buffered saline by intravitreous
injection and served as the control. Eyes were harvested
two months after the injection for various measure-
ments. The retina of C57BL/6 was used for gene expres-
sion assay control.
Fundus photography
A Karl Storz veterinary otoendoscope (Karl Storz, Tut-
tlingen, Germany) coupled with a Nikon D90 digital
camera was used for taking mouse fundus photographs
before the injection and every month after the injection
for two months [24]. The fundus photograph was taken
after pupil dilation (1% tropicamide ophthalmic solution;
Alcon Inc., Fort Worth, TX, USA) and an intraperito-
neal injection of ketamine (1.4 mg/mouse) and xylazine
(0.12 mg/mouse) was used for systemic anesthesia. We
evaluated the lesion changes by comparing sequential
photographs taken in the same fundus area of each eye.
Progression was defined as a > 10% increase in the
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number of retinal lesions (Grade +1), a > 50% increase
in the lesion size in at least one out of three of the
lesions (Grade +2), more than five fused lesions or the
appearance of more than two chorioretinal scars (Grade
+3), or diffuse chorioretinal scars (Grade +4) in compar-
ison with the previous observation. Regression was
defined as a > 10% decrease in the number of retinal
lesions (Grade -1), a > 50% decrease in lesion size in at
least one out of three of the lesions (Grade -2), a > 50%
disappearance of retinal lesions (Grade -3) or a total dis-
appearance of retinal lesions. To avoid bias, evaluation
of the pictures was conducted by a masked observer.
The lesion scores of each eye were estimated by cross-
comparison of the same area based on above criteria.
Histology
Whole eyes were fixed in 4% glutaraldehyde-10% forma-
lin and then embedded in methacrylate. The eyes were
serially sectioned in the vertical pupillary-optic nerve
plane. Each eye was cut into six sections. All sections
containing the entire eye were stained with hematoxylin
and eosin. If an ocular lesion was observed, another six
to twelve sections were cut through the lesion. These
slides were stained with Periodic Acid Schiff stain to
highlight Bruch’s membrane and the basement mem-
brane of small neovascular vessels.
Transmission electron microscopy
The whole eyes were fixed in 2% glutaraldehyde and 2%
paraformaldehyde. The tissue was embedded in Durcu-
pan epoxy resin. Six 1 μm-thick sections stained with
toluidine blue were examined under light microscopy.
Based on the lesions shown on the thick sections, ultra-
thin sections of these lesions were taken and stained
with uranyl acetate and lead citrate for examination
under a JEOL1010 electron microscope (JEOL USA,
Inc., Peabody, MA, USA). Four eyes from two mice
were used for transmission electron microscopy.
Retinal lipofuscin extraction and quantification
A2E ([2,6-dimethyl-8-(2,6,6-trimethyl-1-cyclohexen-1-
yl)-1E,3E,5E,7E-octatetra-enyl]-1-(2-hydroxyethyl)-4-[4-
methyl-6(2,6,6-trimethyl-1-cyclohexen-1-yl) 1E,3E,5E,7E-
hexatrienyl]-pyridinium) is the major component of
lipofuscin fluorophores generated from the visual cycle
flux of all-trans-retinal. The molecule is particularly
relevant to aging and AMD pathogenesis [25]. The mice
were kept in the dark for > 12 hours before they were
killed. The whole eyes were removed in a dark room
under dim red light and homogenized. A2E was
extracted with chloroform and methanol as previously
described [26]. The extracts dissolved in methanol were
separated by HPLC (Agilent 1100 LC, Wilmington, DE,
USA) and detected by an UV detector at a wavelength
of 435 nm. A gradient of 40% to 95% acetonitrile and
H2O in 0.1% trifluoracetic acid was used to elute A2E
on a reverse-phase C18 column (Agilent, eclipse XD8-
C18, 5 μm, 4.6 × 150 mm) at a flow-rate of 1.0 mL/min.
A2E was quantified using external A2E standards [27].
cDNA synthesis
Total RNA from mouse retina and RPE was extracted
using Trizol (Invitrogen, Carlsbad, CA, USA). cDNA
was synthesized using 10 μg total RNA in a total volume
of 100 μL using reverse transcriptase (TaqMan reverse
transcriptase reagents, Applied Biosystems, Foster City,
CA, USA).
TaqMan gene expression array
The array to identify altered immune response gene
expression after TSG-6 treatment was performed using
a TaqMan Array Mouse Immune Response 96-well
Plate according to the manufacturer’s protocols (Applied
Biosystems). The plate contained 92 assays to immune
response-associated genes and four assays to candidate
endogenous control genes. The genes are listed in Addi-
tional file 1: Table S1. The cDNA (100 μL) was mixed
with H2O and 2X TaqMan Universal PCR Mix (Applied
Biosystems) to make 2,500 μL of master mix that was
evenly loaded into each well (25 μL/well). The reaction
was run on an ABI 7500 System (Applied Biosystems).
Expression values were determined with DataAssist v2.0
Software (Applied Biosystems).
Quantification of gene expression by [real-time
quantitative reverse transcription polymerase chain
reaction] qRT-PCR
The synthesis of the cDNA was described above. The
primers and probe for IL-17a and TNF-a were pur-
chased from Applied Biosystems as inventoried TaqMan
gene expression reagents. Relative qRT-PCR was per-
formed according to manufacturer instructions. To
determine the cycle threshold (Ct) values, the threshold
level of fluorescence was set manually in the early phase
of PCR amplification. ABI SDS 1.3.1 software and the 2-
ΔΔCt analysis method were used to determine relative
amounts of product using GAPDH as an endogenous
control. The relative expression was normalized first by
the level of GAPDH from the same cDNA sample and
again normalized to the transcript level in untreated
eyes due to treatment. Each sample was analyzed in
triplicate.
Statistical analysis
The rates of progression and regression between groups
were compared by the Chi-square test. Multiple means
were compared by paired T-test. Differences were con-
sidered significant when P < 0.05.
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Results
Two independent experiments (n = 22 in the first
experiment, n = 9 in the second experiment) were per-
formed and yielded repeatable results.
TSG-6 arrested retinal lesions
The right eyes that received TSG-6 showed retinal lesion
arrests as compared with the contralateral left eyes (con-
trol), in which the retinal lesions progressed two months
after injection (Figure 1A). The plot of 23 pairs of eyes
showed that 16 treated eyes were healthier, four treated
eyes remained at the same lesion scales and three treated
eyes became worse (increased size and number of the
lesions) relative to the contralateral eye by funduscopic
examination two months after injection (Figure 1B). The
natural course of the retinal lesions in Ccl2-/-/Cx3cr1-/-
mice is to worsen with time [4]; therefore, most untreated
left eyes showed worsened lesions. The average lesion
score changes showed improvement (decreased size and
number of the lesions) in the treated right eyes compared
with the control left eyes (P < 0.01; Figure 1C).
The histological observations indicated better retinal
morphology in the treated eyes than in the non-treated
eyes, characterized by less photoreceptor atrophy,
smaller and fewer retinal lesions and thicker retinal
outer layers (Figure 2). The histological examination
between the right and left eyes from 10 pairs of eyes
revealed a decreased lesion severity in six pairs, similar
lesion severity in two pairs and an increased lesion
severity in only two pairs two months after injection.
The improvement in the eyes with decreased lesion
severity identified on routine histology was confirmed
by transmission electron microscopy. The retinal ultra-
structure illustrated better preserved photoreceptor
layers in the treated eyes compared with the untreated
eyes. The retina of the untreated eyes showed degen-
eration of RPE cells, photoreceptors and Bruch’s mem-
brane (Figure 3).
TSG-6 intervention did not alter the accumulation of
lipofuscin in the retina
There was no statistical difference in the amount of A2E
between the treated eyes and the untreated eyes of
Ccl2-/-/Cx3cr1-/- mice (Figure 4).
TSG-6 intervention substantially decreased IL-17a and
TNF-a expression
To study the role of TSG-6 on immune response in the
Ccl2-/-/Cx3cr1-/- retina, we performed a pathway mRNA
array for immune response. Although the majority of
these genes were suppressed after the treatment, IL-17a
was consistently down-regulated by a substantial degree
in the TSG-6 treated eyes (Figure 5). The quantitative
real time PCR assay in an additional five pairs of eyes
further confirmed a three-fold decrease of IL-17a in the
retinal tissue after the treatment (Figure 6). Interestingly,
TNFa-a expression showed a similar pattern to IL-17a
expression (Figure 6).
Figure 1 Continuous funduscopic monitoring. (A) Representative
funduscopic photographs of a pair of eyes in one mouse
monitored for two months. The TSG-6 treated eye (right) showed
fewer retinal lesions than the control eye (left) after two months. (B)
Pairwise plotting of 23 pairs of eyes showing different progressing
scores between the two eyes. Some eye pairs had identical scores
and the numbers of overlapped dots are listed by the dots. The
triangles indicate stable or worse lesions. The squares indicate
improved lesions. (C) The average scores of retinal lesions in treated
and untreated eyes showing lower scores in the treated eyes.
Figure 2 Histological examination of the eyes. Representative
photomicrographs of the retinas from a pair of eyes from one
mouse: healthier retinal structure was indicated by less
photoreceptor cell degeneration (white asterisks), fewer retinal
lesions (arrows) and a thicker retinal outer layer in the treated eye
(right) in comparison to the untreated eye (left), which shows a
larger area (blankets) with loss of photoreceptor cells two months
after TSG-6 injection. (Hematoxylin & eosin, scale bar = 60 μm).
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Discussion
We found that intravitreous delivery of recombinant
TSG-6 protein could stabilize the progression of retinal
lesions in Ccl2-/-/Cx3cr1-/- mice on rd8 background,
indicated by the better preserved morphology of retinal
structure compared with untreated control eyes. The
improvement of the degenerative lesion was correlated
to the altered immune gene expression, particularly the
decreased expression of IL-17a and TNF-a.
The pro-inflammatory cytokine tumor necrosis factor-
alpha (TNF-a) is one of the primary mediators of the
acute phase response. We previously reported an ele-
vated expression of TNF-a in the retina of Ccl2-/-/
Cx3cr1-/- mice [6]. Of interest in the present study is
that expression of the gene for TNF-a was reduced after
Figure 3 Transmission electron micrographs of the retina. Left
upper panel: the retina of the untreated eye shows degeneration of
RPE and photoreceptors. The photoreceptors are dystrophic with
many dislocated nuclei (asterisk) and loss of both inner and outer
segments. Left lower panel: the RPE cell contains lipofuscin-like
liposomal inclusions (arrows) and decreased basal infoldings
(asterisk). Bruch’s membrane shows electron dense debris (blue
arrows). Right upper panel: the ultrastructure of the retina from a
treated eye is intact with well-preserved photoreceptors including
healthy inner (IS) and outer (OS) segments and RPE cells. Right
lower panel: the RPE cell contains many normal mitochondria
(arrows) and basal infoldings (asterisk).
Figure 4 Quantification of retinal A2E. There was no difference
of A2E levels in the retina between TSG-6 treated eyes (n = 7) and
the untreated eyes (n = 7) two months after treatment.
Figure 5 Gene expression array in the retina. Pair plot of 92-
gene expression of a pair of treated and untreated eyes (mouse
#15). The expression of the majority of immune response genes
does not differ substantially between the pair, as shown in the
distance from the bisecting line. However, expression of IL-17a was
substantially reduced in the treated eye compared with the control
eye. A duplicated array of another pair of eyes showed the same
pattern. The TNF-a expression was also consistently reduced in the
duplicated array of the treated eye compared with the control eye.
Figure 6 qRT-PCR of IL-17a and TNF-a . Significantly lower
expression of IL-17a and TNF-a transcripts can be seen in the eyes
treated with TSG-6 compared with the controls. *P < 0.05.
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the TSG-6 treatment, an observation that is consistent
with the anti-inflammatory effects of the protein
[18,20,21,23]. TNF-a and other pro-inflammatory cyto-
kines induce synthesis of TSG-6 in many different cells,
but TSG-6 creates a negative feedback loop that modu-
lates the inflammatory response. The protein was pre-
viously shown to decrease inflammation by binding to
pro-inflammatory fragments of hyaluronan, increasing
the inhibitory activity of inter-a-inhibitor, and inhibiting
migration of neutrophils [21,23,28]. More recently it was
shown to modulate nuclear factor-B signaling in resi-
dent macrophages by its interaction with CD44 [29].
The anti-inflammatory activity has been directly demon-
strated in a number of rodent models of inflammation
including models of arthritis [23], carrageenan- or IL-1-
induced inflammation in an air pouch [30], myocardial
infarction [19], chemical injury to the cornea [22] and
peritonitis [29].
We have previously reported that inflammation and
oxidative stress are major pathogenetic mechanisms
inducing retinal lesions in Ccl2-/-/Cx3cr1-/- mice
[6,9,13]. In contrast to our previous intervention studies
using this strain [6,7], we did not find an altered A2E
level in this study. A2E, a major component of lipofus-
cin, is generated by a series of oxidative stress-mediated
redox reactions [31] and the concentration of A2E is
high in the retina of Ccl2-/-/Cx3cr1-/- mice [4]. This
might be evidence that the beneficial effects of TSG-6
administration come from anti-inflammatory effects
other than the inhibition of oxidative stress.
A subset of effector helper T-cells, IL-17-producing T-
cell (Th17), is largely implicated in the pathogenesis of
various autoimmune diseases [32]. Autoimmunity has
been cited in the pathogenesis of AMD [33-36]. Signifi-
cantly increased levels of IL-22, a member of the Th17
family, and IL-17 were detected in the serum of AMD
patients as compared with non-AMD controls [37]. We
found that, out of 92 immune genes tested, IL-17a was
significantly down-regulated after TSG-6 treatment.
This suggests that TSG-6 has a role in the regulation of
IL-17 that associates with the retinal lesion. Interest-
ingly, IL-17 was shown to have additive effects with
TNF-a and IL-1 on the up-regulation of TSG-6 expres-
sion in the synovium of patients with rheumatoid arthri-
tis [38].
Our data cannot exclude mechanisms other than the
anti-inflammatory role of TSG-6 in the outcome of the
treatment. TSG-6 contains a hyaluronan-binding link
domain and thus is a member of the hyaluronan-binding
protein family, also called hyaladherins. In addition to its
anti-inflammatory effects in binding fragments of hya-
luronan, the hyaluronan-binding domain is known to be
involved in extracellular matrix stability [39]. Interesting,
a recent study reported that IL-17F, sharing high homol-
ogy with other IL-17 family members including IL-17A,
can regulate extracellular matrix stability and stimulate
cartilage degradation by increasing the expression of
collagenases (matrix metalloproteinase (MMP)-1 and
-13) and stromelysin-1 (MMP-3) and by decreasing the
expression of their inhibitors (tissue inhibitor of metal-
loproteinase-2 and -4), type II collagen, aggrecan and
link protein in chondrocytes [40]. It is believed that
defective biosynthesis and/or degradation of the extra-
cellular matrix has the potential to alter the morpholo-
gic and functional characteristics of Bruch’s membrane,
an initial site of pathological change during AMD devel-
opment. The aging of Bruch’s membrane was associated
with an exponential increase in the percentage of pro-
MMPs bound to the membrane [41].
Conclusion
The findings reported here demonstrate that intravitr-
eous delivery of recombinant TSG-6 has a modest effect
in delaying or improving the progression of retinal
lesions in Ccl2-/-/Cx3cr1-/- mice on rd8 background.
Therefore, TSG-6 may prove to be a supplement to the
beneficial effects in AMD treatment obtained by long-
term dietary therapy with omega-3 polyunsaturated fatty
acids and subretinal injection of adeno-associated virus
encoding soluble VEGF receptor [6,7]. The TSG-6
appeared to act primarily by suppressing inflammation
as indicated by its down-regulation of IL-17a and TNF-
a.
Additional material
Additional file 1: Table S1. The list of mouse immune response genes.
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